News

Two manufacturing sites of Qilu were approved by UK MHRA

ABOUT US

News

Two manufacturing sites of Qilu were approved by UK MHRA

Release time：

2014-12-04

Two auditors of UK MHRA inspected Qilu Tianhe Pharmaceutical Co., Ltd and Qilu Antibiotics Co., Ltd. During Nov. 17 to 21, 2014. Both sites were approved without key discrepancy which means the capacity of Tianhe and Antibiotics are recognized by MHRA and strengthen the foundation of extending international market continuously for Qilu.

Qilu Pharmaceutical was listed in 2014 TOP100 companies in the chemical pharmaceutical industry of China

Ondansetron Hcl for Injection of Qilu was approved by USFDA

Related News

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”

2022-12-19

Qilu Pharmaceutical ranked 5th among China's top 100 list